Portal de Periódicos da CAPES

A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion treated by EveroLimus-Eluting Stent) trial

2010; European Association of Percutaneous Cardiovascular Interventions; Volume: 6; Issue: 1 Linguagem: Inglês

10.4244/eijv6i1a17

1969-6213

Raúl Moreno, Eulogio Garcı́a, Rui Campante Teles, Manuel Almeida, Henrique Carvalho, Manel Sabaté, Roberto Martín-Reyes, José Ramón Rumoroso, Guillermo Galeote, Francisco Javier Goicolea, José Moreu, Vicente Mainar, Josefa Mauri, Rui Cruz Ferreira, Mariano Valdés, Armando Pérez de Prado, Victoria Martín‐Yuste, Santiago Jiménez‐Valero, Ángel Sánchez‐Recalde, Luís Calvo, Esteban López de Sá, Carlos Macaya, J L López-Sendón,

Cardiac Imaging and Diagnostics

Chronic total coronary occlusions constitute a sub-group of lesions at very high risk of restenosis after successful percutaneous coronary intervention. The sirolimus-eluting coronary stent is the only drugeluting stent that has demonstrated to reduce angiographic restenosis and the need for new revascularisation procedures in comparison with bare-metal stents in randomised clinical trials focusing on these lesions. Everolimus-eluting stents have shown to offer optimal angiographic and clinical outcomes in comparison with bare-metal stents and paclitaxel-eluting stents, but no randomised trials have tested the device in chronic total occlusions. The CIBELES (non-acute Coronary occlusIon treated By EveroLimus- Eluting Stent) will randomise 208 patients with chronic total coronary occlusions in 13 centres from Portugal and Spain to receive everolimus- or sirolimus-eluting coronary stents. The primary endpoint will be angiographic in-stent late loss.